Jazz Pharmaceuticals (NASDAQ:JAZZ) used an investor call following the ASCO Gastrointestinal Cancer Symposium to highlight ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma. Among patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma, those ...

Genentech's PD-L1 inhibitor combined with Avastin and chemo improved median progression-free survival by around 20 months ...

Vijayawada: The Departments of Physics, Chemistry and Electronics of Andhra Loyola College jointly organised a two-day ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

Flerie AB's (publ) portfolio company KAHR Bio announced a median overall survival of 17.5 months in its Phase II trial with DSP107, combined with the anti-PD-L1 immunotherapy atezolizumab, in patients ...

SHENZHEN -- Chinese researchers have developed an innovative "intratumoral vaccine" molecule that prevents cancer cells from ...

Zanidatamab plus chemotherapy delays progression or death in patients with untreated locally advanced or metastatic gastroesophageal adenocarcinoma.

A recent Financial Times report stated that Merck MRK is in talks to buy Redwood City, CA-based cancer biotech, Revolution ...

Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major’s shares have gained ...